CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenues:
Net product sales	$ 199,519	$ 5,039	$ 327,450	$ 9,466
Sanofi collaboration revenue	88,988	84,446	173,993	169,775
Bayer HealthCare collaboration revenue	9,124	11,123	21,607	23,604
Technology licensing	5,893	5,228	11,786	13,073
Contract research and other	875	1,974	1,352	4,096
Total revenues	304,399	107,810	536,188	220,014
Expenses:
Research and development	147,373	143,149	286,235	272,541
Selling, general, and admistrative	47,705	24,585	106,133	47,996
Cost of goods sold	21,843	395	34,141	777
Total expenses	216,921	168,129	426,509	321,314
Income (loss) from operations	87,478	(60,319)	109,679	(101,300)
Other income (expense):
Investment income	501	998	1,111	2,035
Interest expense	(11,236)	(4,047)	(22,396)	(7,766)
Total other income (expense)	(10,735)	(3,049)	(21,285)	(5,731)
Net income (loss) before income tax benefit	76,743	(63,368)	88,394	(107,031)
Income tax benefit	0	(863)	0	(1,079)
Net income (loss) - basic and diluted	76,743	(62,505)	88,394	(105,952)
Net income (loss) per share - basic (in dollars per share)	$ 0.81	$ (0.69)	$ 0.94	$ (1.18)
Net income (loss) per share - diluted (in dollars per share)	$ 0.70	$ (0.69)	$ 0.81	$ (1.18)
Weighted average shares outstanding - basic (in shares)	94,589	90,436	94,017	89,799
Weighted average shares outstanding - diluted (in shares)	110,167	90,436	108,998	89,799
Condensed Statements of Comprehensive Income (Loss)
Net income (loss) - basic and diluted	76,743	(62,505)	88,394	(105,952)
Other comprehensive income (loss):
Other comprehensive (loss) income, net of tax	(1,034)	1,271	(509)	1,587
Comprehensive income (loss)	$ 75,709	$ (61,234)	$ 87,885	$ (104,365)